The following links contain useful information about menopause, hormones, and hormone therapy.
The North American Menopause Society (NAMS)
A nonprofit scientific organization devoted to promoting women’s health and quality of life through an understanding of menopause.
MenopauseRx.com
The MenopauseRx.com Web site contains a wealth of information presented in a simple format to help women understand the perimenopause to menopause transition.
MayoClinic.com An online information resource offered by the Mayo Clinic, this online guide contains articles and information about menopause and its treatment.
The National Women’s Health Information Center
A service of the Office on Women’s Health (OWH) in the US Department of Health and Human Services (HHS), the National Women’s Health Information Center (NWHIC) is an up-to-date information resource for women’s health topics. The organization offers free women’s health information on more than 800 topics through their call center and Web site.
National Women’s Health Resource Center
A not-for-profit organization, the National Women’s Health Resource Center is a leading independent health information source for women.
The American College of Obstetricians and Gynecologists (ACOG)
ACOG is the nation’s leading group of professionals providing healthcare for women. The Web site provides a wide range of information and online resources for women’s healthcare professionals.
IMPORTANT SAFETY INFORMATION
Estrogens plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. The Women’s Health Initiative (WHI) study reported increased risks of stroke, deep vein thrombosis (DVT), pulmonary embolism, myocardial infarction, and invasive breast cancer in postmenopausal women (ages 50–79 years) during 5.6 years of treatment with daily conjugated estrogens 0.625 mg combined with medroxyprogesterone acetate (MPA) 2.5 mg relative to placebo. The WHI Memory Study, an ancillary study of WHI, reported an increased risk of probable dementia in postmenopausal women 65 years of age or older.[1]
PROMETRIUM® is contraindicated for patients with any of the following conditions: known hypersensitivity to its ingredients; undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; active deep vein thrombosis, pulmonary embolism or history of these conditions; active arterial thromboembolic disease (i.e. stroke, myocardial infarction) or a history of these conditions; known liver disease or dysfunction; known or suspected pregnancy.[1]
PROMETRIUM® is contraindicated in patients with known or suspected pregnancy.[1]
Pregnancy Category B
PATIENTS WHO ARE ALLERGIC TO PEANUTS SHOULD NOT USE PROMETRIUM® CAPSULES.[1]
The most common adverse events reported at a rate greater than placebo in a clinical trial by postmenopausal women receiving conjugated estrogens 0.625 mg daily plus cyclic PROMETRIUM® 200 mg capsules were: headache, breast tenderness, depression, dizziness, abdominal bloating, chest pain, and diarrhea.[1]
The most common adverse events reported at a rate greater than placebo in a clinical trial by postmenopausal women receiving PROMETRIUM® 400 mg capsules were: dizziness, abdominal pain, headache, breast pain, musculoskeletal pain, and viral infection.[1]
You are encouraged to report suspected adverse reactions. Please contact Solvay Pharmaceuticals, Inc. at 1-800-241-1643 or the FDA at www.fda.gov/medwatch or by calling 1-800-FDA-1088.
